212 related articles for article (PubMed ID: 14766754)
1. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms.
Lin C; Lin K; Luong YP; Rao BG; Wei YY; Brennan DL; Fulghum JR; Hsiao HM; Ma S; Maxwell JP; Cottrell KM; Perni RB; Gates CA; Kwong AD
J Biol Chem; 2004 Apr; 279(17):17508-14. PubMed ID: 14766754
[TBL] [Abstract][Full Text] [Related]
2. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.
Lin C; Gates CA; Rao BG; Brennan DL; Fulghum JR; Luong YP; Frantz JD; Lin K; Ma S; Wei YY; Perni RB; Kwong AD
J Biol Chem; 2005 Nov; 280(44):36784-91. PubMed ID: 16087668
[TBL] [Abstract][Full Text] [Related]
3. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
[TBL] [Abstract][Full Text] [Related]
4. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
Tsantrizos YS
Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
[TBL] [Abstract][Full Text] [Related]
5. HCV-NS3 inhibitors: determination of their kinetic parameters and mechanism.
Flores MV; Strawbridge J; Ciaramella G; Corbau R
Biochim Biophys Acta; 2009 Oct; 1794(10):1441-8. PubMed ID: 19505593
[TBL] [Abstract][Full Text] [Related]
6. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.
Lu L; Pilot-Matias TJ; Stewart KD; Randolph JT; Pithawalla R; He W; Huang PP; Klein LL; Mo H; Molla A
Antimicrob Agents Chemother; 2004 Jun; 48(6):2260-6. PubMed ID: 15155230
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061.
Thibeault D; Bousquet C; Gingras R; Lagacé L; Maurice R; White PW; Lamarre D
J Virol; 2004 Jul; 78(14):7352-9. PubMed ID: 15220408
[TBL] [Abstract][Full Text] [Related]
8. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
López-Labrador FX; Moya A; Gonzàlez-Candelas F
Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
[TBL] [Abstract][Full Text] [Related]
9. A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants.
Ivanisenko NV; Mishchenko EL; Akberdin IR; Demenkov PS; Likhoshvai VA; Kozlov KN; Todorov DI; Gursky VV; Samsonova MG; Samsonov AM; Clausznitzer D; Kaderali L; Kolchanov NA; Ivanisenko VA
PLoS One; 2014; 9(3):e91502. PubMed ID: 24643004
[TBL] [Abstract][Full Text] [Related]
10. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations.
Yi M; Tong X; Skelton A; Chase R; Chen T; Prongay A; Bogen SL; Saksena AK; Njoroge FG; Veselenak RL; Pyles RB; Bourne N; Malcolm BA; Lemon SM
J Biol Chem; 2006 Mar; 281(12):8205-15. PubMed ID: 16352601
[TBL] [Abstract][Full Text] [Related]
11. High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors.
Lee JC; Yu MC; Lien TW; Chang CF; Hsu JT
Assay Drug Dev Technol; 2005 Aug; 3(4):385-92. PubMed ID: 16180993
[TBL] [Abstract][Full Text] [Related]
12. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.
Lin C; Kwong AD; Perni RB
Infect Disord Drug Targets; 2006 Mar; 6(1):3-16. PubMed ID: 16787300
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3.
Yang CM; Yoon JC; Park JH; Lee JM
PLoS One; 2017; 12(4):e0175793. PubMed ID: 28410411
[TBL] [Abstract][Full Text] [Related]
14. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
[TBL] [Abstract][Full Text] [Related]
15. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.
Reiser M; Hinrichsen H; Benhamou Y; Reesink HW; Wedemeyer H; Avendano C; Riba N; Yong CL; Nehmiz G; Steinmann GG
Hepatology; 2005 Apr; 41(4):832-5. PubMed ID: 15732092
[TBL] [Abstract][Full Text] [Related]
16. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease.
Perni RB; Almquist SJ; Byrn RA; Chandorkar G; Chaturvedi PR; Courtney LF; Decker CJ; Dinehart K; Gates CA; Harbeson SL; Heiser A; Kalkeri G; Kolaczkowski E; Lin K; Luong YP; Rao BG; Taylor WP; Thomson JA; Tung RD; Wei Y; Kwong AD; Lin C
Antimicrob Agents Chemother; 2006 Mar; 50(3):899-909. PubMed ID: 16495249
[TBL] [Abstract][Full Text] [Related]
17. Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro.
Koev G; Dekhtyar T; Han L; Yan P; Ng TI; Lin CT; Mo H; Molla A
Antiviral Res; 2007 Jan; 73(1):78-83. PubMed ID: 16945431
[TBL] [Abstract][Full Text] [Related]
18. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient.
Cubero M; Esteban JI; Otero T; Sauleda S; Bes M; Esteban R; Guardia J; Quer J
Virology; 2008 Jan; 370(2):237-45. PubMed ID: 18006035
[TBL] [Abstract][Full Text] [Related]
19. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells.
Lin K; Perni RB; Kwong AD; Lin C
Antimicrob Agents Chemother; 2006 May; 50(5):1813-22. PubMed ID: 16641454
[TBL] [Abstract][Full Text] [Related]
20. Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors.
Ehrenberg AE; Schmuck B; Anwar MI; Gustafsson SS; Stenberg G; Danielson UH
J Enzyme Inhib Med Chem; 2014 Dec; 29(6):868-76. PubMed ID: 24517372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
